News

These data point to milestone event frequency and prevalence by subtype of RDEB, highlighting such events as dysphagia and squamous cell carcinoma.

Drs. Levine and Sisti discuss the ethical challenges of GLP-1 drug allocation, exploring fairness, disparities, and policy solutions for obesity and diabetes treatment.

Adelaide Hebert, MD, discusses the impact of the recent approval for tapinarof cream in the management of atopic dermatitis.

Findings from the LIVERHOPE trial suggest adding simvastatin and rifaximin to standard therapy does not reduce ACLF occurrence.

These data suggest a wearable haptic feedback sensor powered by artificial intelligence may function as a supportive therapeutic device for those with atopic dermatitis.

Completion of the trial was announced in a financial update from Novo Nordisk, who explained the trial missed its primary endpoint for uACR improvement.

Elevated HDL-C raised glaucoma risk, particularly for participants aged ≥55 years, contrary to its typical beneficial role in cardiovascular health.

This Month in Review highlights the top psychiatry news in January.

The trend warrants attention, given treatment difficulties and the association with other substance use issues, says lead author of Rutgers Health study.

A new tool may enable earlier identification of heart failure, potentially reducing hospitalizations and premature death.

New research tested how specialized hypertennsion medical curriculum impacted residents’ treatment of hypertensive urgency in the outpatient setting.

In a Q&A, Kasia Lipska, MD, MHS, discusses the impact of type 2 diabetes on the immune system and findings from her recent research.

Most deprescribing interventions consist of a clinician being alerted to a potential problem with the patient’s medication but does not provide guidance to the clinician about how to communicate with the patient.

In a Q&A, Kang discusses the role of MAVS in host resilience, aging as a contributing factor of lung disease, and the link between viral innate immunity and aging biology.

A survey suggests ablation leads to improved sports performance in athletes with atrial fibrillation.

A new app being developed, JomCare, will ask study participants twice a day about their substance cravings and their intention to engage in drug use.

In this quiz, readers will be asked about the pivotal data used to support the July 2024 approval of deuruxolitinib for alopecia areata.

Children who have had a stroke, especially in late primary school, face a greater r risk of anxiety, a study found.

Laique emphasizes the unmet needs for patients with cirrhotic MASH who are not eligible for resmetirom and what role metabolic surgery may play in their care.

The FDA’s approval marks the second indication for Genentech's refillable ocular implant in addition to wet age-related macular degeneration.

This pulmonology month in review highlights recent research on diagnosing asthma and new pivotal trial data.

These new data were announced by LEO Pharma following the phase 3 DELTA TEEN trial, assessing delgocitinib 20mg/g cream for chronic hand eczema (CHE).

The January 2025 endocrinology month in review highlights the latest from the FDA, key drug price negotiations, and the latest updates to the obesity pipeline.

In this segment of January's Lungcast episode, guests discussed the Global Lung Function Initiative (GLI) network, lung function testing, and the use of race-based normal values.

A list of 10 facts to know about the current landscape of cancer management and oncology research in the US.

A study found propranolol significantly lowers ischemic stroke risk in women with migraine, highlighting its potential for stroke prevention in high-risk groups.

The month in review spotlights the top news and research in nephrology from January, including an FDA approval and new IgAN research.